Summary The expression of three epidermal growth factor (EGF)-related peptides, transforming growth factor a (TGF-a), amphiregulin (AR) and cripto-l (CR-1), was examined by immunocytochemistry (ICC) 
A number of different growth factors have been demonstrated to be synthesised by normal and malignant mammary epithelial cells (Davidson & Lippman, 1989; Salomon et al., 1992) . These locally acting peptides may be important in regulating the growth of mammary epithelial cells through potential autocrine, juxtacrine and/or paracrine pathways (Aaronson, 1991; Sporn & Roberts, 1992) . Epidermal growth factor (EGF) and peptides that are structurally related to EGF, such as transforming growth factor a (TGF-cz), are potent mitogens for mammary epithelial cells (Ciardiello et al., 1990a; Osborne & Arteaga, 1990) . These peptides bind to the EGF receptor and activate its intrinsic tyrosine kinase activity (Massague, 1990; Salomon et al., 1990) . TGF-o has been detected in approximately 40-70% of primary human breast carcinomas, whereas EGF receptor expression occurs in nearly 50% of human breast tumours (Bates et al., 1988; Travers et al., 1988; Barrett-Lee et al., 1990; Ciardiello et al., 1990a; Klijn et al., 1992; Dublin et al., 1993) . Coexpression of TGF-o and EGF receptor occurs in a majority of those breast tumours that are expressing either protein, suggesting that a potential autocrine or juxtacrine loop may exist in vivo in a subset of human breast tumours (Bates et al., 1988; Travers et al., 1988; Barrett-Lee et al., 1990) . EGF receptor status is also an important independent prognostic factor in human breast cancer (Sainsbury, 1990; Klijn et al., 1992) . High levels of EGF receptor expression are generally associated with tumours that have higher proliferative rates, with axillary lymph node involvement and with low diseasefree or overall survival (Nicholson et al., 1988; Sainsbury, 1990; Gasparini et al., 1992) . The activation of different proto-oncogenes and/or loss of expression of specific tumoursuppressor genes also frequently occurs in primary human breast tumours (Callahan & Campbell, 1989) . These genetic alterations may affect the expression of and/or response to growth factors and can have a negative impact on overall patient survival (Aaronson, 1991; Salomon et al., 1992) . In this respect, inactivation of the p53 tumour-suppressor gene on chromosome 17p by point mutations and/or loss of heterozygosity (LOH) occurs in approximately 30-50% of primary human breast carcinomas (Callahan & Campbell, 1989; Biartek et al., 1990; Horak et al., 1991; Osborne et al., 1991; Mazars et al., 1992; Poller et al., 1992) . There is evidence demonstrating that the wild-type p53 gene encodes a nuclear phosphoprotein that functions as a transcription factor which can negatively regulate cell proliferation and which is involved in the pathway for other growth factor-controlled, cell cycle-related genes (Ullrich et al., 1992) .
TGF-a is only one of several proteins that can bind to the EGF receptor (Massague, 1990; Salomon et al., 1990) . Other newly discovered members of the EGF/TGF-a family of proteins include heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AR) and cripto-I (CR-1, or teratocarcinoma-derived growth factor 1) (Ciccodicola et al., 1989; Plowman et al., 1990; Higashiyama et al., 1992) . AR is a 78 or 84 amino acid glycosylated protein that is initially synthesised as a 252 amino acid transmembrane precursor (Plowman et al., 1990) . Unlike EGF or TGF-a but similar to HB-EGF (Higashiyama et al., 1992) , AR can bind to heparin and has a hydrophilic 43 amino acid amino-terminal extension that contains at least two presumptive motifs which are similar to the nuclear localisation sequences associated with DNA-binding proteins (Plowman et al., 1990) . AR can bind to the EGF receptor, but with a lower affinity than EGF, can activate the EGF receptor tyrosine kinase and can transactivate the c-erbB-2 tyrosine kinase in several human breast and ovarian epithelial cell lines (Plowman et al., 1990; Johnson et al., 1993) . Exogenous AR can either stimulate or inhibit the growth of different types of normal and malignant human epithelial cells, depending upon the concentration, presence of other growth factors and nature of the target cell (Plowman et al., 1990; Johnson et al., 1991 Johnson et al., , 1992 Normanno et al., 1992; Li et al., 1992) . AR is expressed in and is able to function as an autocrine growth factor for several human mammary epithelial cell strains and for c-Ha-ras-and c-erbB-2-transformed MCF-1OA human mammary epithelial cells (Li et al., 1992; Normanno et al., 1992) . CR-1 is a 188 amino acid protein that, unlike other members of the EGF/TGF--family, lacks a hydrophobic signal peptide and transmembrane domain, but which contains a central region of approximately 37 amino acids that shares structural homology with peptides within this family (Ciccodicola et al., 1989; Dono et al., 1991) . Although a recombinant or naturally occurring CR-1 protein has not yet been obtained to ascertain its biological properties, overexpression of the human CR-I gene can lead to the in vitro transformation of mouse NIH3T3 fibroblasts or mouse NOG-8 mammary epithelial cells, demonstrating that CR-1, like TGF-a and AR, can function as an autocrine growth factor and/or dominantly transforming oncogene (Ciccodicola et al., 1989; Ciardiello et al., 1990b Ciardiello et al., , 1991a Jhappan et al., 1990; Matsui et al., 1990) . In addition, CR-1 is expressed in a majority of human colorectal and gastric carcinoma cell lines and tumours (Ciccodicola et al., 1991b; Kuniyasu et al., 1991; .
TGF-a, AR and CR-1 mRNA transcripts are expressed in a number of different human breast cancer cell lines (Bates et al., 1988; Davidson & Lippman, 1989; Murphy & Dotzlaw, 1989; Plowman et al., 1990; Normanno et al., 1993) . Since there is little or no information on the frequency and level of expression of AR or CR-1 in primary human breast lesions, we have analysed a small panel of infiltrating human breast carcinomas and non-involved breast tissues adjacent to carcinomas for TGF-x, AR and CR-1 expression. Immunocytochemistry (ICC) using peptide-specific polyclonal antibodies that are capable of detecting these proteins in formalin-fixed, paraffin-embedded tissues was used to ascertain if these peptides can be localised in mammary epithelial cells and to determine if there is any differential expression of these proteins between non-involved and malignant breast tissues. 
Materials and methods

Human breast tissues
Polyclonal antibodies
Rabbit antibody R9 was generated against recombinant human TGF-o that had been conjugated to keyhole limpet haemocyanin (KLH) as previously described (Finzi et al., 1991) . The anti-AR antibody (AR-Ab-1) was raised against a 19-mer synthetic peptide that corresponds to residues [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] in the human AR protein as previously described (Johnson et al., 1991 . The specificity and reactivity of the affinitypurified AR-Ab-1 immunoglobulin G (IgG) was evaluated as previously described (Johnson et al., 1991 (Johnson et al., 1991) . The anti-CR-1 antibody (CR-1 Ab) was generated against a 17-mer synthetic peptide that corresponds to amino residues 97-113 in the human CR-1 protein and that represents the carboxy terminus of the 37 amino acid EGF-like region as previously described in PBS and incubated for 2 min in 0.05% diaminobenzidine and in 0.01% hydrogen peroxide. The slides were then rinsed in distilled water, counterstained with haematoxylin and mounted. The anti-TGF-a R9 primary antibody was utilised at a 1:200 dilution. In some cases, the R9 antibody was preabsorbed with 10 jgmlm' human TGF-a (Bachem, Torrance, CA, USA) for 2 h at 37°C. The AR-Ab-I IgG was used at 0 lag ml-', which in some instances was preabsorbed with 20 fig ml-' 19-mer AR synthetic peptide for 2 h at 37°C.
The CR-I Ab was utilised at a 1:400 dilution and, in some cases, was preabsorbed with 20 ig ml1' 17-mer CR-I synthetic peptide for 2 h at 37C. Slides were graded for staining specificity and intensity and for the percentage of immunopositive cells as previously described (Johnson et al., 1991; . Non-specific staining was evaluated for each specimen using either a similar concentration or dilution of preimmune rabbit serum or IgG, or determine the median cut-off point, 9.0%, for Ki-67 nuclear staining. Using this value, tumours were classified in either a high or low index rank.
Oestrogen receptor (ER) assay Cytosolic ER was assayed by the dextran-coated charcoal (DCC) method as previously described (Merlo et al., 1992) .
Southern blot analysis and DNA probes High molecular weight DNA was extracted and blotted as previously described (Merlo et al., 1992) . The DNA was immobilised by UV cross-linking followed by prehybridisation and hybridisation with the following 32P-labelled DNA probes: pYNZ22.1/D17S30 marker probe (ATCC no. 57575 probe, Rockville, MD, USA) (Osborne et al., 1991; Merlo et al., 1992) and the probe p144D6 (Merlo et al., 1992) .
Single-strand conformation polymorphism (SSCP) analysis of genomic and cDNA for p53 point mutations The polymerase chain reaction (PCR)/SSCP method was modified to screen for point mutations in the p53 gene as previously described (Osborne et al., 1991 BrdU incorporation In addition to monitoring for Ki-67 labelling of nuclei, the proliferation index was also assessed by measuring the levels of incorporation of BrdU (0.1 mM) into fresh tumour fragments from each specimen after a 3 h incubation in short-term tissue culture as previously described (Merlo et al., 1992 in breast tissues was similar to TGF-a (Table I) Figure If) . AR expression in the breast carcinomas was then evaluated since a specific 1.4 kb mRNA transcript for this growth factor has recently been shown to be expressed in several normal human mammary epithelial cell strains and in several human breast cancer cell lines (Plowman et (Table II) . A variable number of tumours were present within (Bartek et al., 1990; Osborne et al., 1991; Mazars et al., 1992 (Aaronson, 1991; Sporn & Roberts, 1992 (Mizukami et al., 1990; Umekita et al., 1992) . This difference in the frequency of TGF-a protein expression might be due to the use of monoclonal anti-TGFa antibodies in these studies as compared with the utilisation of a polyclonal anti-TGF-.a antibody in the present study. Formalin fixation might mask specific epitopes in tissues that monoclonal antibodies would normally recognise, whereas the polyclonal antibody might be less sensitive to such changes since multiple epitopes are usually being detected. In contrast to the high frequency of TGF-a expression in breast carcinomas, low levels of TGF-a protein were found in breast epithelium in that only 26% of adjacent non-involved mammary epithelium stained positively for TGF-a, and generally at a lower level of intensity than the corresponding carcinomas. This finding is in agreement with those of Barrett-Lee et al. (1990) , who found low levels of expression of TGF-a mRNA in 33% (two out of six) of normal human breast specimens, and with the results of Mizukami et al. (1990) , in which there was little immunoreactive TGF-a in ten normal breast tissue specimens. In the present study, there was no significant correlation between the average percentage of carcinoma cells in any given carcinoma specimen that were expressing TGF-a and other clinical parameters. A similar lack of association between TGF-x mRNA expression and other clinical and pathophysiological parameters has been noted in several previous studies (Bates et al., 1988; Travers et al., 1988; Ciardiello et al., 1989; Barrett-Lee et al., 1990) .
AR is a newly discovered EGF-related growth factor that is expressed in normal mammary and ovarian epithelial cells (Cook et al., 1991; Johnson et al., 1991; Li et al., 1992; Kenney et al., 1993) , in several human ovarian, colon and breast carcinoma cell lines (Ciardiello et al., 1991b; Johnson et al., 1991 Johnson et al., , 1992 Cook et al., 1992; Normanno et al., 1993) and in a majority of primary human colorectal carcinomas (Ciardiello et al., 1991b; Johnson et al., 1992; anti-AR mouse monoclonal antibody. In their study, there was no association between AR expression and several prognostic factors with the exception of lymph node status, expression being more common in lymph node-positive cases than in lymph node-negative cases. In the present study, involving both normal and malignant breast tissues, staining was restricted to the mammary epithelial cells, was in most cases cytoplasmic and was generally more frequent and intense in the carcinoma cells than in the surrounding noninvolved breast epithelium. In addition, in the carcinoma cells, frequent nuclear staining was also observed in a number of the specimens. Immunolocalisation of AR in the nucleus has been noted in normal colonic and ovarian surface epithelial cells, in several human breast and colon cancer cell lines and in colon and ovarian carcinomas (Johnson et al., 1991 Normanno et al., 1992 Normanno et al., , 1993 . Nuclear localisation of this protein may be due to the presence of two consensus sequences in the amino-terminal region that could serve as potential nuclear targeting regions to translocate the peptide into the nucleus (Plowman et al., 1990; Modrell et al., 1992) . In this respect, addition of exogenous ['25I]AR to human A431 epidermoid carcinoma cells or to human HTB-132 breast carcinoma cells leads to nuclear sequestration of the intact peptide and binding to two nuclear phosphoproteins (Modrell et al., 1992) . This may not be unique to AR since other growth factors such as HB-EGF, nerve growth factor, interleukin 1, basic fibroblast growth factor (bFGF) and the int-2 FGF-related protein also possess nuclear localisation sequences and can be detected in the nucleus (Imamura et al., 1990; Powell & Klagsbrun, 1991; Higashiyama et al., 1992; Acland et al., 1993; RakowiczSzulczynska, 1993) . In this regard, multiple forms of bFGF have been found in the nuclei of target cells, and deletion of the amino terminal nuclear retention sequences from either bFGF or from AR can abolish their mitogenic activity (Imamura et al., 1990; Powell & Klagsbrun, 1991; Kimura, 1993) .
The inverse association between the average number of carcinoma cells that express AR and the p53 status of the breast tumour is intriguing. A significantly greater percentage of carcinoma cells in breast tumours that contained a normal p53 gene express AR than in tumour specimens that possessed p53 mutations. Inactivation of p53 tumour-suppressor activity in human breast tumours can occur by missense mutations in one allele, which is frequently followed by LOH or by a reduction to homozygosity in the second allele (Callahan & Campbell, 1989; Osborne et al., 1991; Mazars et al., 1992; Ullrich et al., 1992) . It is possible that the wild-type p53 protein might positively regulate the expression of AR. In this regard, wild-type p53 can repress the promoter for interleukin 6, another autocrine growth factor (Santhanam et al., 1991) . It is also of interest to note that there is a significant association in primary breast carcinomas between EGF receptor levels and the presence of p53 mutations, suggesting that a mutant p53 protein might up-regulate EGF receptor expression (Horak et al., 1991; Poller et al., 1992) . Finally, expression of p53 mutations in one study was found to be rare in infiltrating lobular carcinomas (Poller et al., 1992) , which may relate to the findings in the present study demonstrating that the average percentage of carcinoma cells that were expressing AR in individual tumours was significantly higher in infiltrating lobular carcinomas, which tend to be histologically more differentiated, than in infiltrating ductal carcinomas. A similar situation has been found in human primary colorectal tumours, in which a higher frequency of AR expression was detected in well-differentiated carcinomas than in poorly differentiated tumours .
Expression of CR-I has been detected in only a limited number of malignant cells, such as undifferentiated mouse and human embryonal carcinoma cells, several human gastric, colon and breast cancer cell lines and primary human colorectal and gastric carcinomas (Ciccodicola et al., 1989 (Ciccodicola et al., , 1991b Kuniyasu et al., 1991; Normanno et al., 1993 (Ciardiello et al., 1991b; Cook et al., 1992; . At least two of these three EGF-related peptides, TGF-a and AR, are bona fide growth factors that function exclusively through the EGF receptor (Massague, 1990; Plowman et al., 1990; Salomon et al., 1990; Johnson et al., 1993) . The apparent redundancy in the expression in mammary epithelial cells of two structurally and biologically related peptides suggests that these peptides may be involved in the regulation of additional biological properties other than cell proliferation such as differentiation. This may be the case since in normal colon specimens immunoreactive AR protein is not found in the proliferative stem cell population of the crypts but is preferentially expressed in the terminally differentiated, nonproliferative columnar and secretory epithelial cells of the villous mucosa and is found at a higher frequency in better differentiated colon carcinomas 
